Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30636646 | 0.95 | NLRP3 (0.57) | NLRP3LMNAGPR139AKR1B1MAPT | |
| SCHEMBL24076327 | 0.91 | NLRP3 (0.64) | NLRP3GPR139AKR1B1 | |
| SCHEMBL30168567 | 0.91 | NLRP3 (0.64) | NLRP3GPR139AKR1B1 | |
| SCHEMBL26732911 | 0.86 | NLRP3 (0.63) | NLRP3GPR139AKR1B1MAPTAURKA | |
| SCHEMBL24076964 | 0.86 | NLRP3 (0.68) | NLRP3GPR139AKR1B1MAPT | |
| SCHEMBL29426566 | 0.86 | NLRP3 (0.63) | NLRP3GPR139AKR1B1MAPTAURKA | |
| SCHEMBL24076307 | 0.84 | NLRP3 (0.58) | NLRP3GPR139FPR2 | |
| SCHEMBL24076367 | 0.84 | NLRP3 (0.57) | NLRP3LMNAGPR139AKR1B1MAPT | |
| SCHEMBL30636643 | 0.83 | NLRP3 (0.46) | NLRP3LMNAGPR139 | |
| SCHEMBL25746242 | 0.83 | LMNA (0.54) | NLRP3LMNAGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-115667225-A | Compound (I) | 詹森药业有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | NLRP3 1/4885LMNA 1597/4885GPR139 1471/4885 |
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | NLRP3, NLRP1, NOD1 | NLRP3 1/4885LMNA 1886/4885GPR139 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.